NCT07117474CompletedPhase 1
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a Single Subcutaneous Injection of HRS-9563 in Subjects With Mild Hypertension: a Randomized, Double-blind, Placebo-controlled Phase I Study.
Source: ClinicalTrials.gov · Last updated 24 Aug 2026
Brief summary (registry, in English)
To evaluate the safety and tolerability of a single subcutaneous injection of HRS-9563 in hypertensive subjects
- Status (registry)
- Completed
- Phase (registry)
- Phase 1
- Study type
- Interventional
- Enrollment
- 60 (actual)
- First submitted
- 9 Jul 2025
- Start date
- 24 Dec 2024
- Primary completion date
- 9 Jun 2026
- Lead sponsor
- Fujian Shengdi Pharmaceutical Co., Ltd.
- Diseases
- High blood pressure
- NCT number
- NCT07117474
What you commit to
- Study type: Interventional · Phase 1
- Participants enrolled: 60
- From 24 Dec 2024 to the primary completion date, 9 Jun 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Recently received any antihypertensive medications or medications that affect blood pressure.
Other illness
- Secondary hypertension;
Lab values
- History of type 2 diabetes mellitus or poorly controlled blood glucose;
Other
- Abnormal daily life rhythm;
- Any blood biochemical indicator during screening or baseline did not meet the standards in the exclusion criteria;
- Mean sitting diastolic blood pressure ≥ 100 mmHg;
- Orthostatic hypotension;
Who the study is looking for
- Males or infertile women aged 18-65 years (inclusive);
- Body mass index in the range of 19-28 kg/m2 (inclusive);
- Mild primary hypertension, without antihypertensive treatment, with a mean sitting systolic blood pressure ≥ 130 mmHg and ≤ 159 mmHg during screening and baseline, and a mean 24-hour ambulatory systolic blood pressure ≥ 130 mmHg during screening.
Age in the registry: 18 years to 65 years · Sex: All · Accepts healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Zhejiang Provincial People's Hospital Coordinator of this site? Confirm its status | Hangzhou | China | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.